SRI International Announces New Manager of Operations for Quality Clinical Labs (QCL)
MENLO PARK, Calif. -- February 13, 2007 -- SRI International, an independent, nonprofit research and development organization, announced today that Caroline Satyadi has joined SRI as manager of operations for Quality Clinical Labs (QCL) in Mountain View, California. QCL was acquired by SRI in April 2006, and is the only commercial laboratory of its type in the state performing clinical pathology analyses in compliance with Good Laboratory Practice (GLP) regulations. QCL specializes in clinical hematology and chemistry evaluations, which are a key component of the preclinical safety studies required by the U.S. FDA in the development of new drugs. The company serves approximately 50 biotechnology and pharmaceutical clients throughout the San Francisco Bay area.
At SRI, Ms. Satyadi will be responsible for the day to day operations of the lab including supervision of all staff, technical oversight, liaison with clients, and interfacing with SRI's Quality Assurance Unit to assure compliance with Good Laboratory Practice regulations. Prior to joining SRI, Ms. Satyadi served as director of laboratory services at Colusa Regional Medical Center in Colusa, California. She has also served as manager of laboratories at IMPATH, NAMSA, and MDS Diagnostic Laboratories and as a research biostatistician for USC School of Medicine.
"We are very pleased that Caroline has joined the QCL team at SRI," said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI International’s Biosciences Division. "Her impressive credentials and nearly 20 years of experience managing clinical laboratories will be a strong asset as we provide SRI clients and partners with the safety studies required to move drugs closer to the clinic and the marketplace."
Ms. Satyadi has a B.S. degree in medical microbiology, an M.S. in biostatistics, an M.B.A., and certifications as a medical technologist, specialist in microbiology, diplomate in laboratory management and specialist in laboratory safety (all ASCP), certification and license as a Clinical Laboratory Scientist (NCA and State of California).
###
About SRI's Biosciences Division
SRI International’s Biosciences Division is an organization of approximately 200 people with all of the resources necessary to take biological and chemical research programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials. SRI Biosciences is a unique organization: it conducts basic research like a university, performs drug discovery and develops biologics like a biotechnology company, and is a contract research organization (CRO) that offers a full range of preclinical development and pharmaceutical sciences services. SRI Biosciences specializes in cancer, immunology, infectious disease, and neurosciences research.
To date, SRI has developed nine drugs internally that have entered clinical trials, with several more currently undergoing preclinical evaluation. Marketed examples of these drugs include bexarotene and halofantrine. Additionally, working with government and industry partners, SRI has helped advance more than 100 drugs into clinical trials, and more than 30 drugs onto the market. Through collaborations with other divisions at SRI, Biosciences is also working at the interfaces of science to create technical platforms for the next generation of drug discovery and development in areas such as drug delivery, diagnostics, and systems biology.
About SRI International
Silicon Valley-based SRI International (www.sri.com) is one of the world’s leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.
